Comparison of different anti-vascular endothelial growth factors for the treatment of wet age-related macular degeneration

To compare the development of patients with wAMD treated with aflibercept (Eylea) or ranibizumab (Lucentis) or bevacizumab (Avastin): which patient groups achieve best visual acuity? Is any difference between patients who receive a certain medication compared to others?